NCT05742841View on ClinicalTrials.gov

EMERALD (Emergency Medicine Cardiovascular Risk Assessment for Lipid Disorders)

PHASE4CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

March 8, 2023

Primary Completion Date

June 1, 2023

Study Completion Date

July 15, 2023

Conditions
Lipid Disorder
Interventions
DRUG

moderate- or high-intensity statin/ rosuvastatin

moderate- or high-intensity statin (either rosuvastatin 10mg daily or rosuvastatin 40 mg daily)

Trial Locations (1)

27157

Wake Forest University Health Sciences, Winston-Salem

All Listed Sponsors
lead

Wake Forest University Health Sciences

OTHER